GeniusVacMel4(GeniusVacMel4) - 在研适应症：黑色素瘤_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名

GeniusVac Mel4、GeniusVac-Mel4、PDC*mel

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

黑色素瘤

非在研适应症-

原研机构

PDC Line Pharma SASU初创企业

在研机构

University of Grenoble

PDC Line Pharma SASU初创企业

非在研机构

Centre Hospitalier Universitaire de Grenoble

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 GeniusVacMel4 相关的临床试验

NCT01863108 / Completed临床1期IIT

Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma

The primary objective of this study is to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a dendritic cell-based cancer vaccine, in patients with melanoma. The secondary objectives are to determine immune response and clinical efficacy of such injections in patients with melanoma.

开始日期2013-06-01

申办/合作机构

Centre Hospitalier Universitaire de Grenoble

[+3]

100 项与 GeniusVacMel4 相关的临床结果

登录后查看更多信息

100 项与 GeniusVacMel4 相关的转化医学

登录后查看更多信息

100 项与 GeniusVacMel4 相关的专利（医药）

登录后查看更多信息

1

项与 GeniusVacMel4 相关的文献（医药）

2011-05-01·La Revue de Médecine Interne4区 · 医学

GENiusVac, une stratégie vaccinale antitumorale innovante basée sur des cellules dendritiques plasmocytoïdes allogéniques

4区 · 医学

Article

作者: J. Plumas ; J. Charles ; D. Laurin ; M.-J. Richard ; C. Aspord ; L. Chaperot ; M.-T. Leccia

The development of effective vaccines against cancer and viruses still remains a challenge. Many immunotherapeutic strategies have been developed but without sufficient therapeutic success. Plasmacytoid dendritic cells (pDC) play a crucial role in antitumor and antiviral responses. Despite their outstanding functional properties, their therapeutic potential has not yet been worked out. We propose a new immunotherapeutic strategy based on a pDC cell line irradiated and pulsed with tumor or viral antigens. GENiusVac allows the induction of multispecific and highly functional cytotoxic cell responses directed against viral or tumor targets. We demonstrated the potential of this strategy in vitro, its therapeutic efficacy in vivo in a humanized mouse model, and its clinical relevance ex vivo from melanoma patients' cells. GENiusVac highlights pDCs as potent vector of immunotherapy and provide a way to exploit them in cell therapy to fight cancer or chronic viral infections.

100 项与 GeniusVacMel4 相关的药物交易

登录后查看更多信息